1St Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Radiotherapy Planning Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Radiat Oncol. 2022 Jun 3;17(1):103. doi: 10.1186/s13014-022-02069-4.
Surgical resection with adjuvant concurrent radiochemotherapy is the standard of care for stage III-IV oral cavity cancer. In some cases, the dynamic course of the disease is out of the prepared schedule of treatment. In that event, a stereotactic radiosurgery boost might be the only chance for disease control.
Here, we present a case study of a patient with oral cancer who underwent surgery. During adjuvant radiotherapy, a metastatic cervical lymph node was diagnosed based on fine-needle aspiration biopsy. To increase the total dose to the metastatic tumor, a stereotactic radiosurgery boost of 1 × 18 Gy was performed two days after the last fraction of conventional radiotherapy. The early and late tolerance of this treatment were positive. During the 18-month follow-up, locoregional recurrence was not detected. The patient died due to secondary malignancy.
This paper shows that a stereotactic radiosurgery boost added to adjuvant conventional radiotherapy is an effective approach permitting the maintenance of good local control in well-selected patients.
手术切除联合辅助同期放化疗是 III-IV 期口腔癌的标准治疗方法。在某些情况下，疾病的动态病程超出了既定的治疗计划。在这种情况下，立体定向放射外科增敏治疗可能是控制疾病的唯一机会。
本文报道了 1 例口腔癌患者的病例研究。该患者在接受辅助放疗期间，经细针抽吸活检诊断为颈部转移性淋巴结。为了提高转移性肿瘤的总剂量，在常规放疗最后一次分割后两天，进行了 1×18 Gy 的立体定向放射外科增敏治疗。这种治疗的早期和晚期耐受性均为阳性。在 18 个月的随访期间，未发现局部区域复发。患者因继发性恶性肿瘤死亡。
本文表明，辅助常规放疗中增加立体定向放射外科增敏治疗是一种有效的方法，可使选择合适的患者保持良好的局部控制。
